The following article features coverage from the American Urological Association (AUA) 2019 meeting. Click here to read more of Renal & Urology News’ conference coverage.

CHICAGO—Adverse events (AEs) associated with abiraterone or enzalutamide treatment for metastastic castration-resistant prostate cancer (mCRPC) vary by patient age, according to real-world data presented at the 2019 American Urological Association annual meeting.

Cosimo De Nunzio, MD, and colleagues from Sant’Andrea Hospital, ‘Sapienza’ University in Rome, Italy, employed the Eudra-Vigilance database to study adverse reactions to abiraterone, enzalutamide, and radium 223 according to patient age group: younger than 65 years; 65 to 85 years; and older than 85 years.

Compared with the youngest patients, men aged 65 to 85 years taking abiraterone or enzalutamide had significantly higher risks for cardiac and metabolism disorders and lower risks for musculoskeletal and connective tissue diseases. Patients older than 85 years taking abiraterone or enzalutamide had significantly higher risks for cardiac, general, and infectious disorders, but lower risks for hepatobiliary and musculoskeletal disorders. The team found no significant differences in risk between men aged 65 to 85 years and those older than 85 years.

No age-related differences in adverse events were observed among patients taking radium 223. The most frequent AEs with radium 223 were general disorders (e.g., asthenia, fatigue, pain), which affected 22% of all age groups.

“Analysis of real-life adverse events related to abiraterone, enzalutamide, and radium 223 is essential for proper management of patients with castration-resistant prostate cancer,” co-author Riccardo Lombardo, MD, told Renal & Urology News. “Our real-world data suggest that older patients have different adverse event profiles when treated with abiraterone and enzalutamide. Clinicians should be aware of these differences.”

Read more of Renal & Urology News’ coverage of the AUA 2019 meeting by visiting the conference page.

Reference

De Nunzio C, Tema G, Lombardo R, et al. Age influence on adverse events in patients treated with abiraterone plus prednisone, enzalutamide and Radium223 for metastatic castration resistant prostate cancer: analysis of real life data from Eudra Vigilance database. Presented at: AUA 2019. May 3-6, 2019. Chicago. Poster MP22-18.